Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient mepolizumab, (OBO) ATC R03DX09 for the period 01.02.2025 - 31.01.2027 - 767986

World Biggest Tenders Source

This tender with title Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient mepolizumab, (OBO) ATC R03DX09 for the period 01.02.2025 - 31.01.2027 - 767986 has been published on Bidding Source portal dated 23 Dec 2024 for the country of Germany. It has been categorized on Pharmaceutical products. For similar tenders you can see tenders mentioned below of this page.

General Information

Germany

Tender Title :

Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient mepolizumab, (OBO) ATC R03DX09 for the period 01.02.2025 - 31.01.2027 - 767986

Tender Type :

Invitation for Bids

Country :

Germany

Publish Date :

23 Dec 2024

Closing Date :

4 Dec 2026

Notice Language :

English

Tender Categories (CPVs) :

Pharmaceutical products

Full Tender Details :

For viewing full details of tenders, you should Log in to your account. If not registered yet, Please Register Now

Or Request a call back now and one of our representatives will contact you. Contact us

Similar Tenders

Open house drug discount agreements Buserelin, ATC L02AE01 - 768779 Germany Open house drug discount agreements Tapentadol in non-sustained release dosage forms, ATC N02AX06 - 768083 Germany Open house drug discount agreements Trientin, ATC A16AX12 - 767476 Germany Open house drug discount agreements carbamazepine, ATC N03AF01 - 766649 Germany Open framework agreement on drug discounts in accordance with Section 130a Paragraph 8 of the Social Security Code (SGB V) with the option to join at any time, so-called approval model 2025-02 of the German Pension Insurance Knappschaft-Bahn-See - 762710 Germany Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the Social Security Code (SGB V) for the active ingredient Perindopril and Indapamide (excluding Perindopril as arginine salt), ATC C09BA54 fd Z. 01.02.25 - 31.01.27 - 769495 Germany Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient baricitinib, (OBO) ATC L04AA37 for the period 01.02.2025 - 31.01.2027 - 769460 Germany Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the Social Security Code (SGB V) for the active ingredient PEG-Epoetin beta, (OBO) ATC B03XA03 for the period 01.02.2025 - 31.01.2027 - 769125 Germany Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient flupentixol, (OBG) ATC N05AF01 for the period 01.02.2025 - 31.01.2027 - 768331 Germany Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V for the active ingredient aripiprazole (excl. Dafo for the production of a DIS), (OBO) ATC N05AX12 for the period 01.02.2025 - 31.01.2027 - 767376 Germany

Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient mepolizumab, (OBO) ATC R03DX09 for the period 01.02.2025 - 31.01.2027 - 767986

General Information

Germany

Similar Tenders

Pharmaceutical products Tenders

Germany Tenders

Europe Tenders

Tenders

info@biddingsource.com